Evaluating bone health in adolescents with cystic fibrosis
Official title: Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis
Run by Massachusetts General Hospital · NCT06216704 · Data updated 2026-11-12
This study is testing how bone health in teenagers with cystic fibrosis compares to their healthy peers to see if higher fat in their bone marrow affects their bone strength.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 13 Years to 20 Years |
| Sex | All |
| Enrollment | 36 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Drugs / interventions | Prednisone |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | December 31, 2028 |
| Study ends | June 30, 2029 |
| Registry record updated | October 30, 2025 |
| Trial ID | NCT06216704 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adolescents aged 13-20 with cystic fibrosis and pancreatic insufficiency who have a stable treatment regimen.
✕Probably not a fit
Patients with other chronic diseases affecting bone health or those currently using medications that alter skeletal metabolism may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess bone marrow composition and bone mineral density in adolescents diagnosed with cystic fibrosis (CF) compared to healthy controls. Using advanced imaging techniques such as magnetic resonance imaging, dual-energy X-ray absorptiometry, and peripheral quantitative computed tomography, the study will investigate the relationship between increased bone marrow fat and decreased bone health. The research will focus on understanding the underlying mechanisms affecting bone development in adolescents with CF, particularly during this critical growth period. A total of 36 adolescents with CF will be matched with 36 healthy peers based on various demographic factors.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of bone health in adolescents with cystic fibrosis.
How similar studies have gone: While the specific focus on bone marrow composition in adolescents with cystic fibrosis is novel, related studies have shown varying degrees of success in understanding bone health in CF patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 13-20 years old * Cystic fibrosis with pancreatic insufficiency * Must have a stable treatment regimen, including CFTR modulator usage unchanged for the prior three months * Liver transplant recipients will be eligible, as long as they are at least 1 year post-transplant and are no longer on Prednisone for immunosuppressive therapy Exclusion Criteria: * Diagnosis of other chronic disease affecting bone health * Active use (within the past 3 months) of medications that are known to affect skeletal metabolism * CF exacerbation or glucocorticoid exposure within the prior 1 month * Lung transplant
Where it's running
-
Boston Children's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Rebecca Gordon, MD — Boston Children's Hospital
- Study coordinator: Rebecca Gordon, MD
- Email: rebecca.gordon@childrens.harvard.edu
- Phone: (617) 355-7476
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older
This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.
-
VX-272 dose escalation in healthy adults
This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.
-
Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis
This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.
-
Dose escalation of VX-581 to check safety and drug levels in healthy adults
The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.
-
PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care
This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.
-
Collecting sputum samples at home for cystic fibrosis patients
This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.